The greatest challenge for #mRNA-LNP therapies is targeting non-liver tissues. To overcome this, we used customisable bispecific antibodies to tether mRNA-LNPs to cell-surface proteins, achieving efficient and selective mRNA delivery in vivo. @BASEmRNA https://t.co/0nJj8eVsqC

To accelerate #mRNA vaccine and therapy research, I'm excited to share our end-to-end protocol for #mRNA design, synthesis and encapsulation in @NatureProtocols. Protocol development by @LauraJLeighton, Natasha Chaudhary and Tim Mercer. @BASEmRNA https://t.co/lsPOKdmz5H

A huge milestone for personalised #mRNA therapeutics for inherited disease! A baby with an ultra-rare mitochondrial disease was treated at UPenn with an mRNA-encoded gene-corrector. The mRNA was made to treat a single individual in just 7 months! https://t.co/2K77Rxyx8Y

Crucially, this approach doesn't require a new LNP, it works with FDA-approved formulations. We hope that this approach will enable targeted mRNA therapeutics for diverse diseases. Work led by Bettina Dietmair, James Humphries and Chirs Howard. @BASEmRNA @AIBNatUQ @TRI_info

The technology is programmable and works with other targeting arms including anti-PSMA (highly expressed on prostate cancer cells) bispecifics.

Bispecifics can be used by combining with the mRNA-LNP (pre-mixing) or the bispecific can be administered first (pre-targeting). 5/

As proof of concept we used anti-EGFR bispecifics to deliver mRNA to mouse breast cancer xenografts. The mRNA-payload (luciferase) is very efficiently delivered in vivo. 4/

To overcome this obstacle we developed bispecific antibodies that bind to PEG on the surface of LNPs and to cell-surface markers. 3/

Getting a high dose of mRNA to target tissues is one of the toughest problems for broad use of mRNA-LNP therapies. When adminstered systemically mRNA-LNPs go the liver with little delivery to other tissues. 2/

Systemic mRNA-LNP delivery beyond the liver? Check out our recent paper demonstrating cell-specific mRNA-LNP delivery using PEG- and target cell-specific antibodies. This approach can customised to any target cell-type with off-the-shelf mRNA-LNPs. 1/ https://t.co/MIyfH9vWz3

Exited to share our latest preprint! mRNA-LNPs are efficiently delivered to healthy livers, but what about liver tumours? Our postdoc Laura Leighton found liver tumours efficiently take up mRNA, enabling next generation mRNA-LNP cancer therapeutics. https://t.co/bwdF4EA5UA

Interested in undertaking a #PhD in the transformative field of #mRNA cancer vaccines? I have an earmarked PhD #scholarship available for an outstanding domestic student to join our team at @UQ_News and @BASEmRNA . If this sounds like you, get in touch. https://t.co/PkBhOHdmpp

Opportunity for a bioinformatician to join the lab @PeterMacRes to help us identify new Immunotherapies. Please reach out for further details. Ad is for a post doc but research assistants considered. 💻 🧬. See link below.

Wow this is super cool! Single-cell resolution imaging of #mRNA-LNP biodistribution in cleared mouse bodies. https://t.co/W6v8TkTzuy

Exciting news! @BASEmRNA and Vaxxas have been awarded the $2M USD Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Concept Stage Prize to develop thermostable needle-free mRNA vaccines! @AIBNatUQ https://t.co/1MCQldUyL1

It was fantastic collaborate with @Fer_NK_nando on this programme to develop CAR-NK therapies for sarcoma with #mRNA tech. These mRNA-enhanced NK cells can eliminate cancer cells in vitro and in vivo. Out now in Clinical and Translational Medicine. @TRI_info @AIBNatUQ @BASEmRNA

Awesome work from @MJMitchell_Lab at UPenn in @Nature identifies novel LNPs that can deliver #mRNA to the placenta. Using the placenta-targeting LNPs to deliver VEGF mRNA improves pre-eclampsia in animal models. https://t.co/RbDtBF7H1Q

Earlier this year I had the opportunity to present a TEDx talk on the transformative potential of personalised #mRNA vaccines for cancer. The recording is out now: https://t.co/mmWlJznpKN @AIBNatUQ @BASEmRNA @UQ_News

@BASEmRNA Work led by Helen Gunter @Mercerlab1, @AIBNatUQ @TRI_info @UQ_News Try it out here: https://t.co/LMl2WpqGHe

There are more ways to design an mRNA than atoms in the universe, so how do you choose the best one? Our new @BASEmRNA software, mRNArchitect enables you to tune expression, stability, reactogenicity and synthesisability to design more potent #mRNA drugs https://t.co/ZzJNXSYv2J

We're building Australia's first centre for the designing and manufacturing personalised cancer vaccines @BASEmRNA @AIBNatUQ. On the PhaseIII podcast I discuss the transformative potential of mRNA for cancer and our efforts to bring this tech to patients https://t.co/v82RMe42yB